OTIC Otonomy Inc.

2.21
-0.02  -1%
Previous Close 2.23
Open 2.21
Price To Book 1.15
Market Cap 67,953,984
Shares 30,748,409
Volume 14,445
Short Ratio
Av. Daily Volume 55,495
Stock charts supplied by TradingView

NewsSee all news

  1. AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss

    GAINESVILLE, Fla. and CAMBRIDGE, Mass. and SAN DIEGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of

  2. Otonomy to Present at the Cantor Global Healthcare Conference

    SAN DIEGO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber,

  3. Otonomy Initiating Phase 1/2 Clinical Trial of OTO-413 in Hearing Loss

    SAN DIEGO, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 trial initiation announced September 17, 2019 with data due 2H 2020.
OTO-413
Hidden hearing loss
Phase 3 data released August 30 failed to meet primary and key secondary endpoints.
OTO-104 AVERTS-1
Meniere's disease
Phase 1/2 trial initiation announced April 11, 2019 with data due 1H 2020.
OTO-313
Tinnitus
Additional Phase 3 trial data due 1H 2020.
OTIVIDEX
Ménière's disease
Phase 2 trial completed October 2016. Phase 3 trial planned.
OTIPRIO
Pediatric patients with acute otitis media with tympanostomy tubes (AOMT)
Approved December 11, 2015
OTIPRIO (ciprofloxacin otic suspension)
Ear Tube Placement Surgery
Approval announced March 2, 2018.
OTIPRIO
Acute otitis externa

Latest News

  1. AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss

    GAINESVILLE, Fla. and CAMBRIDGE, Mass. and SAN DIEGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of

  2. Otonomy to Present at the Cantor Global Healthcare Conference

    SAN DIEGO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber,

  3. Otonomy Initiating Phase 1/2 Clinical Trial of OTO-413 in Hearing Loss

    SAN DIEGO, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase